非小细胞肺癌免疫治疗进展.pdfVIP

277 中国肺癌杂志2 0 1 4 年 3 月第 1 7卷第 3 期 Chin J Lung Cancer, March 2014, Vol.17, No.3 · · DOI: 10.3779/j.issn.1009-3419.2014.03.17 · 综 述 · 非小细胞肺癌免疫治疗进展 何圆 尤长宣 【 】肺癌是全球范围内癌性死亡的首要因素，发病率、死亡率高，预后较差，急需开发一种新的高效 摘要 低毒疗法。作为术后辅助或是姑息治疗手段，免疫治疗为非小细胞肺癌患者提供了一个新的治疗方向。免疫疗法 作用机理各不相同，如免疫检测点受体抑制剂（抗CTLA4抗体、抗PD-1抗体、抗PD-L1抗体）、主动性免疫疫苗 L-BLP25 Belagenpumatucel-L MAGE-A3 CIK （ 脂质体疫苗、 疫苗、 蛋白疫苗）、过继性免疫疫苗（ 细胞）等，研究表 明免疫治疗非小细胞肺癌肿瘤缓解率较前提高，前景值得期待，II期/III期临床试验亦在进一步探索其临床应用价 值。本文就当前非小细胞肺癌免疫疗法原理、临床试验、不良反应及待解决问题作一概述。 【关键词 】肺肿瘤；免疫治疗；进展 Advances in Immunotherapies for Non-small Cell Lung Cancer 1 2 Yuan HE , Changxuan YOU 1Graduate Student of Southern Medical University, Guangzhou 510515, China; 2Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China Corresponding author: Changxuan YOU, E-mail: ycx6026@126.com Abstract Globally, Lung cancer is the leading cause of cancer-related death of high morbidity and mortality with 【 】 poor prognosis, which needs some more effective and less toxic therapies. The immunotherapies offer a novel approach for the treatment of patients with non-small cell lung cancer (NSCLC) in both the adjuvant and palliative disease settings. A number of promising